235 related articles for article (PubMed ID: 19966564)
1. Corneal and conjunctival sensitivity in patients with dry eye: the effect of topical cyclosporine therapy.
Toker E; Asfuroğlu E
Cornea; 2010 Feb; 29(2):133-40. PubMed ID: 19966564
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in post-refractive surgery chronic dry eye patients with ocular pain.
Zhao L; Chen J; Duan H; Yang T; Ma B; Zhou Y; Bian L; Cai X; Qi H
BMC Ophthalmol; 2024 Jan; 24(1):28. PubMed ID: 38247010
[TBL] [Abstract][Full Text] [Related]
3. Association of Dry Eye Symptoms and Signs in Patients with Dry Eye Disease.
Tawfik A; Pistilli M; Maguire MG; Chen Y; Yu Y; Greiner JV; Asbell PA; Ying GS;
Ophthalmic Epidemiol; 2024 Jun; 31(3):274-282. PubMed ID: 37592829
[TBL] [Abstract][Full Text] [Related]
4. Impact of Topical Cyclosporine-A or Topical Chloroquine on Post-LASIK Ocular Surface Stability - A Randomized Controlled Trial.
Titiyal JS; Goswami A; Kaur M; Sharma N; Maharana PK; Velpandian T; Pandey RM
Curr Eye Res; 2023 Jun; 48(6):557-563. PubMed ID: 36800492
[TBL] [Abstract][Full Text] [Related]
5. Exploration of efficacy and mechanism of 0.05% cyclosporine eye drops (II) monotherapy in allergic conjunctivitis-associated dry eye.
Jiao X; Qi Y; Gao N; Zhang C; Zhao S; Yang R
Eye (Lond); 2024 Apr; 38(5):937-944. PubMed ID: 37904000
[TBL] [Abstract][Full Text] [Related]
6. The Effect of Tear Supplementation on Ocular Surface Sensations during the Interblink Interval in Patients with Dry Eye.
Dienes L; Kiss HJ; Perényi K; Szepessy Z; Nagy ZZ; Barsi Á; Acosta MC; Gallar J; Kovács I
PLoS One; 2015; 10(8):e0135629. PubMed ID: 26302222
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of a new water-free topical cyclosporine 0.1% solution for optimizing the ocular surface in patients with dry eye and cataract.
Akpek EK; Sheppard JD; Hamm A; Angstmann-Mehr S; Krösser S
J Cataract Refract Surg; 2024 Jun; 50(6):644-650. PubMed ID: 38334413
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the mucosal chemokines CCL28, CXCL14, and CXCL17 in dry eye disease: An in vitro and clinical investigation.
Domínguez-López A; Blanco-Vázquez M; Calderón-García AÁ; García-Vázquez C; González-García MJ; Calonge M; Enríquez-de-Salamanca A
Exp Eye Res; 2024 Apr; 241():109854. PubMed ID: 38453037
[TBL] [Abstract][Full Text] [Related]
9. Topical insulin, a novel corneal epithelial regeneration agent in dry eye disease.
Burgos-Blasco B; Diaz-Valle D; Rego-Lorca D; Perez-Garcia P; Puebla-Garcia V; Fernandez-Vigo JI; Benitez-Del-Castillo JM; Gegundez-Fernandez JA
Eur J Ophthalmol; 2024 May; 34(3):719-725. PubMed ID: 37814519
[TBL] [Abstract][Full Text] [Related]
10. Effect of upper eyelid blepharoplasty on the ocular surface, tear film, and corneal microstructure.
Aygun O; Arat YO; Dikmetas O; Karakaya J; Baytaroglu A; Irkec M
Arq Bras Oftalmol; 2024; 87(3):e20220220. PubMed ID: 38537039
[TBL] [Abstract][Full Text] [Related]
11. Predictive performance of corneal and lid margin sensitivity for dry eye disease: An investigator-masked, prospective, prognostic accuracy study.
Wang MTM; Meyer JJ; Xue AL; Power B; Craig JP
Ocul Surf; 2024 Jul; 33():11-15. PubMed ID: 38554989
[TBL] [Abstract][Full Text] [Related]
12. Lacripep for the Treatment of Primary Sjögren-Associated Ocular Surface Disease: Results of the First-In-Human Study.
Tauber J; Laurie GW; Parsons EC; Odrich MG; ;
Cornea; 2023 Jul; 42(7):847-857. PubMed ID: 35942530
[TBL] [Abstract][Full Text] [Related]
13. Impact of Topical 0.05% Cyclosporine A Eye Drops on Post-Femtosecond-Assisted Laser In Situ Keratomileusis Ocular Surface Recovery: A Randomized Clinical Trial.
Zhao L; Duan H; Ma B; Yang T; Zhou Y; Liu Y; Chen J; Chen Y; Qi H
Eye Contact Lens; 2024 Jun; ():. PubMed ID: 38865592
[TBL] [Abstract][Full Text] [Related]
14. Electroencephalogram-detected stress levels in the frontal lobe region of patients with dry eye.
Kaido M; Arita R; Mitsukura Y; Tsubota K
Ocul Surf; 2024 Apr; 32():139-144. PubMed ID: 38458565
[TBL] [Abstract][Full Text] [Related]
15. Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial.
Avni I; Garzozi HJ; Barequet IS; Segev F; Varssano D; Sartani G; Chetrit N; Bakshi E; Zadok D; Tomkins O; Litvin G; Jacobson KA; Fishman S; Harpaz Z; Farbstein M; Yehuda SB; Silverman MH; Kerns WD; Bristol DR; Cohn I; Fishman P
Ophthalmology; 2010 Jul; 117(7):1287-93. PubMed ID: 20304499
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic effects of low-color-temperature light-emitting diodes on dry eye.
Pang Y; Cao T; Hu H; Peng Z; Xu K; Jiang Y; Wang F; Jin M; Zeng L; Zhang X
J Biophotonics; 2023 Dec; 16(12):e202300188. PubMed ID: 37654080
[TBL] [Abstract][Full Text] [Related]
17. The Immunological Basis of Dry Eye Disease and Current Topical Treatment Options.
Periman LM; Perez VL; Saban DR; Lin MC; Neri P
J Ocul Pharmacol Ther; 2020 Apr; 36(3):137-146. PubMed ID: 32175799
[TBL] [Abstract][Full Text] [Related]
18. Effects of Topical 0.05% Cyclosporine A on Dry Eye Symptoms and Parameters Following Small Incision Lenticule Extraction.
Zhu X; Li S; Wang M; Yao W; Huang X; Zhao L
J Refract Surg; 2024 Apr; 40(4):e229-e238. PubMed ID: 38593259
[TBL] [Abstract][Full Text] [Related]
19. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model.
Sosne G; Ousler GW
Clin Ophthalmol; 2015; 9():877-84. PubMed ID: 26056426
[TBL] [Abstract][Full Text] [Related]
20. Topical Insulin for Ocular Surface Disease.
Cid-Bertomeu P; Vilaltella M; Martínez M; Mir M; Huerva V
J Ocul Pharmacol Ther; 2024 May; 40(4):204-214. PubMed ID: 38527183
[No Abstract] [Full Text] [Related]
[Next] [New Search]
